A large body of evidence suggests that not only direct anticoagulant effects but also major
bleeding events and stroke prevention depend on plasma concentrations of direct oral …

Direct oral anticoagulants (DOACs) have largely replaced vitamin K antagonists, mostly
warfarin, for the main indications for oral anticoagulation, prevention and treatment of …

Concomitant use of direct oral anticoagulants (DOACs) and medications with
inhibition/induction effect on P‐gp/CYP3A might increase risk of bleeding/treatment failure …

Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation
and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are …

The widespread expression and polyspecificity of the multidrug ABCG2 efflux transporter
make it an important determinant of the pharmacokinetics of a variety of substrate drugs. Null …

Cancer patients have an increased risk of developing venous thromboembolic events.
Anticoagulation management includes prophylactic or therapeutic doses of low molecular …

Ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is approved in
the US, EU, and other regions for the treatment of adults with type 2 diabetes mellitus …

Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …

Endothelial cells are main components of the Blood-Brain Barrier (BBB) and form a tight
monolayer that regulates the passage of molecules, with the ATP-Binding Cassette (ABC) …

Novel oral anticoagulants (NOACs) are drugs approved for the prevention and treatment of
many thromboembolic cardiovascular conditions as a safer alternative to warfarin. We …